AVA-6000 is under clinical development by Avacta Life Sciences and currently in Phase I for Soft Tissue Sarcoma. According to GlobalData, Phase I drugs for Soft Tissue Sarcoma have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AVA-6000’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AVA-6000 is under development for advanced or metastatic solid tumours which are known to be FAP positive including pancreatic, colorectal, breast, ovarian, bladder and non-small cell lung cancers, squamous cell carcinoma of the head and neck and soft-tissue sarcoma.. The drug candidate is an affimer conjugated to pro-doxorubicin. It acts by targeting FAP. The drug candidate is developed based on the Tufts technology and pre|CISION technology . It is administered through intravenous route.
Avacta Life Sciences overview
Avacta Life Sciences is developing safe and efficacious drugs.
For a complete picture of AVA-6000’s drug-specific PTSR and LoA scores, buy the report here.